Analyst Elemer Piros is excited about Ocular Therapeutix’s near-term potential to get Dextenza approved to treat post-surgical pain. Last month, Ocular Therapeutix resubmitted its application for Dextenza to the Food and Drug Administration after being issued a complete response letter — the FDA’s euphemism for a rejection — last July.
Category: Glaucoma
Here’s Why Inotek Pharmaceuticals Corp. Is Being Obliterated
Shares are collapsing in early-morning trading on Tuesday, falling more than 68% as of 10:05 a.m EST after the company reported results from a phase 3 study that failed to meet its primary endpoint. announced top-line results of its MATrX-1 trial on Tuesday.